Substituted N-heteroaryl sulfonamide compounds inhibit WDR5-MYC interactions, and the compounds and their pharmaceutical compositions are useful for treating disorders and conditions in a subject such as cancer cell proliferation.

Substituted N-heteroaryl sulfonamide compounds inhibit WDR5-MYC interactions, and the compounds and their pharmaceutical compositions are useful for treating disorders and conditions in a subject such as cancer cell proliferation.

The present disclosure relates to compounds of Formula (I): ##STR00001##
and to their pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for inhibiting the maturation of cytokines of the IL-1 family by inhibiting inflammasomes and may be used in the treatment of disorders in which inflammasome activity is implicated, such as inflammatory, autoinflammatory and autoimmune diseases and cancers.

The present disclosure relates to compounds of Formula (I): ##STR00001##
and to their pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for inhibiting the maturation of cytokines of the IL-1 family by inhibiting inflammasomes and may be used in the treatment of disorders in which inflammasome activity is implicated, such as inflammatory, autoinflammatory and autoimmune diseases and cancers.

The present invention provides an SSAO inhibitor and an application thereof in preparing a drug for treating a disease related to SSAO. In particular, the present invention provides a compound shown in formula (IV) and a pharmaceutically acceptable salt thereof. ##STR00001##

The present invention provides AHR agonists, compositions thereof, and methods of using the same.

The present invention provides AHR agonists, compositions thereof, and methods of using the same.

A method of water uptake is provided. The method includes contacting a hydrogen-bonded organic framework (HOF) with water to form a mixture where the HOF comprises hydrogen bonded units of trimesic acid and guanazole. The HOF has a sheet structure, where the sheets form an intercrossed macroporous network with pores on a surface. The HOF absorbs at least a portion of the water in the mixture.

A method of water uptake is provided. The method includes contacting a hydrogen-bonded organic framework (HOF) with water to form a mixture where the HOF comprises hydrogen bonded units of trimesic acid and guanazole. The HOF has a sheet structure, where the sheets form an intercrossed macroporous network with pores on a surface. The HOF absorbs at least a portion of the water in the mixture.

A hydrogen-bonded organic framework (HOF) and a method of making the HOF. The HOF has at least one amine substituted organic linker and at least one carboxylic acid-based organic linker. The HOF is prepared by dissolving the linkers separately in water and mixing the aqueous solutions, without using any organic solvents, additional catalysts, or any other reagents.